Patients UK-wide whole genome sequencing for newborns is feasible - b... Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann
Views & Analysis How to balance the patient voice atop the shifting plates of... The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm?
Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access.
Market Access Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaph... Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitti
Views & Analysis 2021 market access prospects for France In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
